Differential, stage‐dependent expression of Hsp70, Hsp110 and Bcl‐2 in colorectal cancer

Hwang, Tae Sook; Han, Hye Seung; Choi, Ho Lim; Lee, Yong J.; Kim, Yun-Jeong; Han, Mi-Young; Park, Young‐Mee

doi:10.1046/j.1440-1746.2003.03011.x

Cited by 112 publications

(79 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few previous studies, which were conducted with small colorectal cancer sample sizes, reported that HSP110 overexpression was associated with worse overall survival, advanced stage and nodal metastasis in colorectal cancer. 36,37 In these circumstances, the study by Dorard et al 25 provided important clues about the effect of HSP110 mutations on colorectal cancer. It is reasonable that the increased expression of mutant HSP110 inhibits the normal functions of HSP, which are beneficial to cancer cell survival; therefore, this molecular alteration can result in positive effects on survival in patients with cancer.…”

Section: Discussionmentioning

confidence: 99%

Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer

Kim

Rhee

et al. 2014

Modern Pathology

View full text Add to dashboard Cite

It has been recently suggested that the expression levels of mutant HSP110 could be a prognostic marker in colorectal cancer with a high level of microsatellite instability (MSI-H). The aim of our study was to validate the prognostic significance of HSP110 mutation using immunohistochemistry and DNA testing in MSI-H colorectal cancer. Wild-type HSP110 (HSP110wt)-specific immunohistochemistry was performed in 168 MSI-H colorectal cancer tissues, and their expression levels were evaluated using a four-tier scoring system (0/1 þ /2 þ /3 þ ). Of these tissues, 167 cases were analyzed for HSP110 T 17 deletion. Associations with clinicopathological, molecular and survival parameters were statistically analyzed. The low-level expression of HSP110wt (0/1 þ ) was observed in 40 MSI-H colorectal cancers (24%) and was significantly related to large HSP110 T 17 deletions (Z 4 bp, Po0.001). In survival analysis, patients with low HSP110wt expression (0/1 þ ) showed better diseasefree survival compared with those with high expression (2 þ /3 þ ; P ¼ 0.005). This significance in survival difference was maintained in patients with 5-fluorouracil-based chemotherapy-treated tumors (P ¼ 0.024) and in those with stage III/IV tumors (P ¼ 0.032). Multivariate analysis confirmed the role of HSP110wt expression as an independent prognostic factor (P ¼ 0.016, hazard ratio ¼ 4.32). In MSI-H colorectal cancer, a low expression of HSP110wt is associated with large HSP110 T 17 deletions and better clinical outcome. Immunohistochemistry of HSP110wt can be a simple and valuable tool for the prognostic and therapeutic stratification of patients with MSI-H colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer

Kim

Rhee

et al. 2014

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Overexpression of HSP70 has been shown as a marker for advanced disease and lymph node metastasis in colorectal carcinoma (Lazaris et al 1997;Hwang et al 2003), BC and undifferentiated ovarian cancer (Athanassiadou et al 1998). In cervical cancer, it is correlated with tumor size and increased proliferation (Ralhan and Kaur 1995).…”

Section: Al 2010)mentioning

confidence: 99%

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Günaldı

Afşar

Okuturlar

et al. 2015

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent cause of cancer death in women throughout the world. Thus, it is necessary to establish sensitive screening, diagnosis and treatment methods for BC. Heat shock protein 70 (HSP70) is an important cellular stress response protein that protects cells from apoptosis. Recent studies have shown that serum HSP70 levels may provide clinically important information in various types of cancer. HSP70 is also overexpressed in BC, which is known to be associated with cancer progression, apoptosis and cell proliferation. However, the serum level of HSP70 and its diagnostic and prognostic potential in BC have not been investigated yet. The aim of this study was to determine the usefulness of serum HSP70 level as a diagnostic test and its predictive value in patients with BC. This prospective study consisted of 45 female patients diagnosed with BC and 16 healthy women who were matched for age and body mass index (BMI). Enzyme-linked immunosorbent assay (ELISA) technique was used to measure the serum level of HSP70. The serum level of HSP70 was significantly higher in patients with BC than in the healthy control group (5.98 ± 2.05 vs. 1.49 ± 0.47 ng/ml, p = 0.001). HSP70 level > 2.41 ng/ml was the best cutoff value to predict BC (97.78% sensitivity and 93.75% specificity). This study shows that HSP70 can be used as an adjunct to other diagnostic tests for BC and may be helpful for identifying patients at increased risk of BC.

show abstract

“…Furthermore, there are a number of reports indicating that high expression of Hsp72 in human tumors, especially of epithelial origin, correlates with high invasiveness, metastasis, poor prognosis of the disease and resistance to chemotherapy (Ciocca et al, 1993;Costa et al, 1997;Vargasroig et al, 1997;Nanbu et al, 1998). For example, in colorectal and lung cancers, expression of Hsp72 closely correlates with advanced clinical stages and positive lymph node involvement (Volm et al, 2002;Hwang et al, 2003). These findings suggest that Hsp72 provides a selective advantage to tumor cells during cancer progression.…”

Section: Introductionmentioning

confidence: 99%

Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents

2005

View full text Add to dashboard Cite

Differential, stage‐dependent expression of Hsp70, Hsp110 and Bcl‐2 in colorectal cancer

Cited by 112 publications

References 56 publications

Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer

Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer

Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer

Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents

Contact Info

Product

Resources

About